Attached files
file | filename |
---|---|
EX-99.2 - Cytosorbents Corp | v204295_ex99-2.htm |
EX-99.1 - Cytosorbents Corp | v204295_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 29,
2010
CYTOSORBENTS
CORPORATION
(Exact
name of registrant as specified in its charter)
Nevada
|
000-51038
|
98-0373793
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
7
Deer Park Drive, Suite K
Monmouth
Junction, New Jersey 08852
(Address
of principal executive office) (Zip Code)
(732)
329-8885
Registrant’s
telephone number, including area code:
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13c-4(c))
|
Item
7.01 Regulation FD Disclosure.
CytoSorbents
Corporation (the “Company”) made available to the public certain new information
via its website. The Company posted an executive summary and investor
presentation update to its website on Wednesday, November 24, 2010. A copy of
the executive summary and investor slides is being furnished as Exhibits 99.1
and 99.2, respectively, hereto.
The
information in this Form 8-K (including Exhibit 99.1) shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item
9.01 Financial Statement and Exhibits.
(a)
|
Financial
Statements of Business Acquired.
|
Not
applicable.
|
|
(b)
|
Pro
Forma Financial Information.
|
Not
applicable.
|
|
(c)
|
Shell
company transactions.
|
None.
|
|
(d)
|
Exhibits.
|
99.1
|
Investor
slide presentation posted to the Company’s website on Wednesday, November
24, 2010. The slide presentation is furnished and not filed pursuant to
Instruction B.2 of Form 8-K.
|
99.2
|
Executive
summary posted to the Company’s website on Wednesday, November 24, 2010.
The executive summary is furnished and not filed pursuant to Instruction
B.2 of Form 8-K.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
CytoSorbents
Corporation
|
|||
By:
|
/s/
Phillip Chan
|
||
Name:
Phillip Chan
|
|||
Title:
Chief Executive Officer
|
|||
Dated:
November 30, 2010